Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications
April 03, 2023 07:00 ET
|
Genenta Science
MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
March 02, 2023 06:45 ET
|
Genenta Science
MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic...
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
February 07, 2023 07:00 ET
|
Genenta Science
MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene...
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients
November 07, 2022 08:05 ET
|
Genenta Science
• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical studies• Macrophage and T cell profiles in patients’ tumor microenvironment echo...
Genenta Provides First Half 2022 Business Update and Financial Results
October 24, 2022 07:30 ET
|
Genenta Science
Current dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7...
Genenta to Present at Upcoming Scientific and Investor Conferences
October 05, 2022 08:05 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of...
Genenta to Present at Upcoming Investor Conferences
September 07, 2022 07:00 ET
|
Genenta Science
MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of...
AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative
July 25, 2022 06:00 ET
|
Genenta Science
MILAN, Italy, July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion...
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
May 13, 2022 07:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
May 09, 2022 07:30 ET
|
Genenta Science
MILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...